Source of the article: Heart Future; Editor: Sophia
Reprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.
Recently,Medtronic (NYSE: MDT)Announcing the launch of itsThe Latest Innovative Products in the Field of Cardiac Surgery——Avalus Ultra New Generation Surgical Aortic Tissue ValveIt is developed by Medtronic based on 10 years of clinical experience with the Avalus valve.
For cardiac surgeons and patients,This product is easy to implant and also more convenient for subsequent management.。
InTranscatheter Aortic Valve Replacement (TAVR) Gradually Becoming the Protagonist Today,The launch of Avalus Ultra demonstratesSurgical Aortic Valve ReplacementSAVR still has vitality and clinical value.。
# Avalus Ultra Aortic Tissue Valve
Avalus Ultra Aortic Tissue ValveReceived FDA approval in January this yearUsed for the treatment of aortic valve stenosis。
The specific product information is as follows:
1. Super Circular DesignCan enhance hemodynamics;2. Three LasersThe thickness and deflection of the bovine pericardial leaflets are matched;3. Two-part polymer frameworkMinimize the stress areas on the flyer;
4. Sewing MarkHelpful for suture placement and valve orientation.
Avalus Ultra has the following highlights:
Durable:Polyether Ether Ketone (PEEK) Polymer ScaffoldWith good strength and flexibility, andAnti-permanent DeformationThe ability;CanReduce the Risk of Potential Metal Corrosion in Transcatheter Stent Materials;
Good visibility:Radiopaque coils, which can be used for future valve-in-valve proceduresProvide clear visibility；Easy to implant:The valve has a low profile, facilitating implantation.; The size and geometry of the valve facilitate future valve-in-valve procedures;The green V-shaped suture on the valve sewing cuff facilitates the identification of the location of aortic calcification;In addition, the valve leaflets are laser-cut and have excellent conformability.Effectively Reduce Valve Damage。The Design of This ValveAiming to achieve 100% engagement and minimize central reflux. ValveSize, Geometric DesignIt is also expected to become an alternative for Valve-in-Valve (ViV).In addition, Avalus Ultra also inherits the characteristic of Avalus being perfectly suitable for valve-in-valve procedures.Specially designed leaflets effectively reduce the risk of coronary artery obstruction in valve-in-valve procedures.。
Vice President and Chief Medical Officer of Cardiac Surgery, Structural Heart, and Mechanical Circulatory Support at Medtronic Cardiovascular Portfolio Pieter Kappetein Indicates:"Patients with aortic valve stenosis are presenting with increasingly complex conditions, necessitating continuous optimization of surgical treatments. Surgeons need innovative technologies like the Avalus Ultra valve,"The design of the valve aims to enhance ease of use and long-term durability, serving patients for their lifetime.。”President of Cardiac Surgery Business, Medtronic Cardiovascular PortfolioDr. Karim BandaliIndicates:"Cardiac surgeons hope enterprises will cooperate with them to provide better innovative technologies."The Avalus Ultra valve is one of several innovative products successfully launched this year.(Including the acquisition and launch of the Penditure LAA Exclusion System)on the basis of。"# Biological Valve MarketCurrently, the global artificial valve market is in an oligopolistic monopoly pattern:Edward Life Sciences, as the leader in the field, accounts for up to 60%; Medtronic follows closely, accounting for about 30%.。The current mainstream in the marketAfter bioprosthetic valve implantationInevitableWill gradually calcify,Usage CycleOnly 10 to 15 years。Therefore,Anti-calcificationIs an important indicator for evaluating artificial biological heart valves, which is also a hot topic in the field of artificial biological valves in recent years.There are currently two main processing technologies globally.：First,Edward's glutaraldehyde cross-linking technology in the United States;Secondly,The carboxyl-coordinated compound cross-linking technology developed by Dr. Lei Jin, the founder of Balloon Medical;Currently, most bioprosthetic heart valves use the first method, but this method tends to cause valve calcification.
Edward has been studying anti-calcification technology, and after improvement, there has been a significant enhancement, with the durability of the valve greatly increased.And the leader of domestically produced biological valves, Baloon MedicalThenMasteredCarboxyl Coordination Compound Crosslinking Technology. According to publicly available information,This technology even in some aspectsSuperior toGlutaraldehyde Cross-Linking Technology。- Bioprosthetic Valve Degradation? Material Improvement is the Key
The Team of the Department of Cardiac and Great Vessel Surgery, Union Hospital, Huazhong University of Science and TechnologyIndependently developedWorld's First New Cellularized Valve。▲Source of the imageUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyThe New Cellularized ValveAfter implantation into the human body,Autologous cells are able to grow within the valve material.Therefore,This valve is not prone to calcification failure, which helps patients restore pulmonary valve function.。As the world's first cellularized valve replacement,HopefulPromote Biomaterials fromInert ReplacementToActive RegenerationA fundamental transformation, and drive the global clinical application update of bioprosthetic valves.Currently, this new type of cellular valveHas begun to enter the clinical trial stageIn 2023, Union Hospital has performed seven cases of new cellularized valve implantation.
Medtronic (NYSE: MDT), founded in 1949 and headquartered in Minneapolis, Minnesota, USA, is a global leading medical technology company with over 95,000 employees.
Medtronic's innovative solutions have expanded to more than 70 key disease areas, committed to providing lifelong treatment options for patients with chronic conditions. Every second, two patients worldwide benefit from Medtronic's medical technologies or therapies.Medtronic's main businesses includeCardiovascular, Medical Surgery, Neuroscience, and DiabetesFour business blocks, includingThe highest proportion is cardiovascular.。
Taking the 2023 financial report as an example, the company's total revenue was $31.227 billion, ranking first in the global medical device enterprise revenue.Among which, the cardiovascular business revenue was 11.573 billion US dollars, accounting for 37.06%, includingCardiac Rhythm and Heart Failure (CRHF), Structural Heart and Aorta (SHA), and Coronary and Peripheral Vascular (CPV)Three departments.
▲2023 Annual Report (Source: Company Official Website)
